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A B S T R A C T
Background: Cardiovascular diseases are the leading cause of death in elderly people. Over the past
decades medical advancements in the management of patients with acute myocardial infarction (AMI)
led to improved survival and increased life expectancy. As short-term survival from AMI improves, more
attention is being shifted toward understanding and improving long-term outcomes.
Aim: To evaluate age-associated variations in the long-term (up to 10 years) prognostic factors following
AMI in ‘‘real world’’ patients, focusing on improving risk stratiﬁcation of elderly patients.
Methods: A retrospective analysis of 2763 consecutive AMI patients according to age groups: 65 years
(n = 1230) and >65 years (n = 1533). Data were collected from the hospital’s computerized systems. The
primary outcome was 10-year postdischarge all-cause mortality.
Results: Higher rates of women, non-ST-elevation AMI, and most comorbidities were found in elderly
patients, while the rates of invasive treatment were lower. During the follow-up period, mortality rate
was higher among the older versus the younger group (69.7% versus 18.6%). Some of the parameters
included in the interaction multivariate model had stronger association with the outcome in the younger
group (hyponatremia, anemia, alcohol abuse or drug addiction, malignant neoplasm, renal disease,
previous myocardial infarction, and invasive interventions) while others were stronger predictors in the
elderly group (higher age, left main coronary artery or three-vessel disease, and neurological disorders).
The c-statistic values of the multivariate models were 0.75 and 0.74 in the younger and the elder groups,
respectively, and 0.86 for the interaction model.
Conclusions: Long-term mortality following AMI in young as well as elderly patients can be predicted
from simple, easily accessible clinical information. The associations of most predictors and mortality
were stronger in younger patients. These predictors can be used for optimizing patient care aiming at
mortality reduction.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Cardiovascular heart disease is the leading cause of death in
both men and women older than 65 years [1,2]. Among people who
died of ischemic heart disease, more than 80% were 65 years of
age [3]. Over the past decades medical advancements in the* Corresponding author at: Nursing Research Unit, Soroka University Medical
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led to improved survival and increased life expectancy [3]. When
placed in the context of current life expectancy, AMI often occurs
over a decade before end of life [3]. As short-term survival from
AMI continues to improve, more attention is being shifted toward
understanding and improving long-term outcomes [4–8].
The elderly, compared with younger individuals, are a unique
population presenting with different clinical characteristics and a
worse prognosis following AMI [2]. Actually, older age, as a factor
we cannot affect, is consistently one of the main negative
prognostic values in most trials and mortality following AMI
increases steeply with age [2,9,10]. This was suggested to be
related, in great part, to increased comorbidities and suboptimal reserved.
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of older patients in clinical trials guiding acute and long-term care
coupled with the uncertainty about the beneﬁts and risks
associated with advancing age, likely explain this practice
[3,12]. Thus, limited information exists regarding the age-
associated disparities in the long-term prognostic factors following
myocardial infarction in the real world.
The aim of the current study was to evaluate age-associated
disparities in the long-term (10-year) prognostic factors following
AMI in ‘‘real world’’ unselected patients, focusing particularly on
improving risk stratiﬁcation of elderly patients pointing out targets
of potential interventions.
Methods
In this retrospective study, we used the database of the
previously published Soroka Acute Myocardial Infarction (SAMI)
Project [13,14], including patients who had been admitted for AMI
in 2002–2004 and discharged alive. Out of 2773 consecutive
patients, 2763 were included, as 10 patients were excluded due to
missing age data. The World Heart Organization (WHO) deﬁnition
was used for creating two groups of patients: younger (65 years)
and older (>65 years of age) [10].
Data were obtained from the hospital’s information systems
and included demographic, cardiovascular risk factors and
comorbidities, AMI clinical characteristics and interventions, and
test results [13]. Grouping of diseases and interventions was based
on the International Classiﬁcation of Disease, Ninth Revision,
Clinical Modiﬁcation (ICD-9-CM) discharge codes as we have
previously elaborated [13]. In addition, diagnoses of anemia were
grouped together with low hematocrit and low hemoglobin blood
levels (for men – hemoglobin <13 g/dL and hematocrit <39%; for
women – hemoglobin <12 g/dL and hematocrit <36%, at
discharge). The group of diagnoses of renal diseases included high
creatinine blood levels (creatinine level 1.2 mg/dL, at discharge).
Similarly, the diagnosis of dyslipidemia was grouped with
abnormal blood lipid levels (low-density lipoprotein cholesterol
>130 mg/dL). Diagnosis of diabetes mellitus (DM) was based on
the diagnosis of the treating physicians without overruling and
was classiﬁed as either with complications or without. Diagnoses
of DM with renal manifestations were classiﬁed as renal diseases;
the diagnoses of DM with peripheral vascular manifestations were
grouped with peripheral vascular diseases (PVDs). Strokes (both
ischemic and hemorrhagic) were included in the category
‘‘neurologic disorders’’. Echocardiography measurements and
deﬁnitions relating to chamber sizes, mass, and function in
addition to valvular function (e.g., mitral regurgitation) were in
accordance with the recommendations and reference values of the
American Society of Echocardiography (ASE) at that time [15,16].
Mortality data were obtained from the hospital’s mortality
database, updated on a weekly basis from the Ministry of the
Interior Population Registry. The primary endpoint was post-
discharge all-cause mortality during up to 10 years follow-up
period. The study protocol conforms to the ethical guidelines of the
Helsinki Declaration and was approved by the local ethics
committee.
Statistical analysis
Statistical analysis of the data was performed using IBM SPSS
Statistics v.20.0 software (IBM, Chicago, IL, USA). Comparisons of
the prevalence rates of the investigated parameters between the
groups were performed using Chi-square test. Mortality in the
whole study population was assessed using Kaplan–Meier
approach to survival analysis and comparison between the groups
was performed with log-rank test. In addition, we comparedsurvival rates of the study groups with the general population
(matched by age, sex, and ethnicity) in Israel (1998–2002), based
on the report of the Central Bureau of Statistics [17], provided the
estimated annual risk of mortality. The data regarding the general
population were considered as expected values; the comparisons
were performed using one-sample log-rank test and are presented
as standardized mortality ratio (SMR) with 95% conﬁdence interval
(CI), as it was proposed in the literature [18,19].
The strength of the association of the investigated variables
with death was assessed as hazard ratio (HR) and 95% CI, using Cox
proportional hazard models. In addition, for each study variable an
interaction model with age group was built.
Multivariate analysis included Cox proportional hazard models.
Two similar models were calculated, one model for each age group.
The variables included in the models were those that were found to
be statistically signiﬁcant prognostic markers of the endpoint, in
the univariate analysis, at least in one age group. Finally, the
interaction model was performed by entering the interaction
terms for all variables. For each test, p values <0.05 were
considered statistically signiﬁcant. Statistical signiﬁcance of the
interaction variables suggested different strengths of relationship
between the age groups.
The accuracy of the multivariable models was assessed using c-
statistic, represented by the area under the receiver operating
characteristic (ROC) regression in which the follow-up period was
included as covariate.
Results
Patient clinical characteristics
The age of the full cohort (n = 2763) was distributed between
25.7 and 101.5 years, mean 66.6  13.3 years. The elder patients
comprised 1533 (55.5%) subjects and the younger group 1230 (44.5%).
Baseline characteristics according to the age groups are presented in
Table 1.
A higher rate of women and non-ST-elevation myocardial
infarction (NSTEMI) was found among the elder versus the younger
age group. Furthermore, a higher rate of most comorbidities was
found among the elders, including comorbidities that required
treatment and intervention modiﬁcations [renal diseases, anemia,
and chronic obstructive pulmonary disease (COPD)], except
signiﬁcantly lower rates of dyslipidemia and smokers. Moreover,
clinical complications were more prevalent in the older group [left
ventricular (LV) dysfunction, congestive heart failure (CHF), and
atrial ﬁbrillation/ﬂutter] and echocardiography parameters repre-
senting the aging heart [elevated LV ﬁlling pressure, left atrial
dilatation, and mitral regurgitation (MR)]. Signiﬁcant three-vessel
or left main coronary artery (LMCA) diseases and lower rates of
invasive therapies were found among the elder than the younger
group. Lower rates of interventional therapies [e.g., coronary artery
bypass surgery (CABG) and percutaneous coronary intervention
(PCI)] were found among the older age group as compared to the
younger group.
Follow-up and mortality
During the follow-up period (up to 10 years; median 8.2 years),
1298 patients died (cumulative mortality of 46.8%). Cumulative
mortality among the elderly was signiﬁcantly higher compared
with the younger group (70.0% versus 19.0%, p < 0.001; Fig. 1). In
the total cohort, the long-term mortality rates were higher
compared to age-, sex-, and ethnicity-matched general population
of Israel with SMR of 2.24 (95% CI: 2.10–2.38; p < 0.001).
Furthermore, the latter differences as compared to matched
general population seemed to be somewhat more prominent in
Table 1
Baseline characteristics of the study population by age groups.
Variable Age 65 years Age >65 years p
n = 1230 n = 1533
Demographic characteristics
Age, years (mean; SD) 53.68; 7.55 76.11; 7.15
Gender, male 1016 (82.6) 858 (56) <0.001
Ethnicity (4.8% missing or unknown) <0.001
Jews 938 (84.3) 1400 (92.3)
Bedouins 175 (15.7) 116 (7.7)
Cardiovascular risk factors
Hypertension 512 (41.6) 898 (58.6) <0.001
Dyslipidemia (14.4% missing) 912 (79.4) 826 (67.9) <0.001
DM – all forms 373 (30.3) 590 (38.5) <0.001
DM without recorded renal or peripheral circulation manifestations 326 (26.5) 462 (30.1) 0.036
PVD 117 (9.5) 310 (20.2) <0.001
Tobacco use disorder 754 (61.3) 331 (21.6) <0.001
Renal diseases (0.9% missing) 169 (13.9) 569 (37.3) <0.001
Obesity 292 (23.7) 231 (15.1) <0.001
Cardiac history
History of PCI 172 (14) 179 (11.7) 0.07
History of CABG 64 (5.2) 155 (10.1) <0.001
Previous MI 205 (16.7) 339 (22.1) <0.001
Other cardiac disorders
Mitral and aortic valves disorders 126 (10.2) 342 (22.3) <0.001
Cardiomegaly 69 (5.6) 148 (9.7) <0.001
CHF 54 (4.4) 235 (15.3) <0.001
Atrial ﬁbrillation and ﬂutter 65 (5.3) 319 (20.8) <0.001
Characteristics of AMI event
STEMI 879 (71.5) 913 (59.6) <0.001
Results of angiography (n) 952 742
Coronary artery disease <0.001
No or nonsigniﬁcant 53 (5.6) 25 (3.4)
Signiﬁcant one vessel 262 (27.5) 102 (13.7)
Signiﬁcant two vessels 278 (29.2) 205 (27.6)
Signiﬁcant three vessels or signiﬁcant LMCA 359 (37.7) 410 (55.3)
Intervention for AMI <0.001
Conservative 419 (34.1) 926 (60.4)
CABG 108 (8.8) 116 (7.6)
Thrombolytic therapy or/and PCI 703 (57.2) 491 (32)
Results of echocardiography (n) 1029 1017
Severe left ventricular dysfunction 75 (7.3) 154 (15.1) <0.001
Concentric or signiﬁcant left ventricular hypertrophy 37 (3.6) 67 (6.6) 0.002
LV dilatation 28 (2.7) 48 (4.7) 0.017
Elevated LV ﬁlling pressure 78 (7.6) 168 (16.5) <0.001
Moderate or severe MR 25 (2.4) 86 (8.5) <0.001
Moderate or severe pulmonary hypertension 12 (1.2) 91 (8.9) <0.001
Left atrial dilatation 85 (8.3) 225 (22.1) <0.001
Signiﬁcant right ventricular dysfunction 118 (11.5) 134 (13.2) 0.24
Moderate or severe tricuspid regurgitation 20 (1.9) 90 (8.8) <0.001
Results of laboratory tests
Plasma sodium (0.7% missing), <135 meq./L 248 (20.4) 440 (28.8) <0.001
Plasma potassium (0.7% missing), >5.1 meq./L 201 (16.5) 428 (28) <0.001
Other disorders
Anemia (0.7% missing) 378 (31) 840 (55.1) <0.001
Gastro-intestinal hemorrhage 17 (1.4) 51 (3.3) 0.001
COPD 57 (4.6) 173 (11.3) <0.001
Malignant neoplasm 18 (1.5) 85 (5.5) <0.001
Alcohol or drug addiction 39 (3.2) 17 (1.1) <0.001
Schizophrenia or psychosis 17 (1.4) 25 (1.6) 0.595
Neurological disorders 15 (1.2) 52 (3.4) <0.001
Data presented as the number of patients and percent of categories for all investigated variables except age.
SD, standard deviation; DM, diabetes mellitus; PVD, peripheral vascular disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; LV, left
ventricular; MR, mitral regurgitation; AMI, acute myocardial infarction; CHF, congestive heart failure; STEMI, ST-elevation myocardial infarction; LMCA, left main
coronary artery; COPD, chronic obstructive pulmonary disease.
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Fig. 1. Cumulative survival functions throughout the follow-up period, in the study
cohort (solid lines) and the general population (dashed lines) for younger (blue/
black) and older groups (red/gray).
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elders (SMR = 2.22, 95% CI: 2.08–2.38) (p < 0.001 for each) (Fig. 1).
Age-related differences in long-term mortality predictors
A linear association was found between age and long-term
mortality; 1-year increase in age was related with OR of 1.08 (95%
CI: 1.08–1.09, p < 0.001) for mortality. Similarly, the latter linear
association was found in each age group (Table 2).
The univariate analysis (Table 2) showed a linear association
between age and long-term mortality in each age group.
Additionally, disparities in mortality predictors between the
groups were found. The association between the following
signiﬁcant predictors and mortality was found to be stronger in
the younger than older population: cardiovascular risk factors
(DM, PVD, and renal diseases); cardiac history (previous MI, CHF,
and atrial ﬁbrillation or ﬂutter); CABG as a treatment of AMI (lower
mortality compared to conservative treatment); pathologic results
of echocardiography (LV dysfunction and dilatation, MR, and
pulmonary hypertension); electrolyte disturbances (hyponatremia
and hyperkalemia); and other noncardiovascular comorbidities
(anemia, COPD, malignant neoplasm, and schizophrenia or
psychosis).
Furthermore, the following characteristics were found to be
signiﬁcant predictors only in the younger group: Arab ethnicity,
hypertension, history of CABG, cardiomegaly, and alcohol/drug
addiction, while obesity (lower mortality) and signiﬁcant three-
vessel coronary artery or LMCA diseases (compared to no or
nonsigniﬁcant) predicted long-term mortality only in the older
population.
Multivariate analysis
The results of the multivariate analysis are presented in Table 3.
For most signiﬁcant predictors, the association with the risk of
mortality was found to be stronger in the younger population,
compared with the older population: renal diseases, previous MI,
CABG treatment, hyponatremia, anemia, and malignant neoplasm.
Furthermore, alcohol or drug addiction and schizophrenia or
psychosis were signiﬁcantly associated with higher risk of death
only in the younger age group, while older age, signiﬁcant three-
vessel or LMCA diseases, left atrial dilatation, and neurological
disorders only in the older age group.
The c-statistics of the multivariate models for 10-year all-cause
mortality were 0.75 and 0.74 in the younger and the older groups,
respectively. The c-statistic of the interaction model was 0.86.Discussion
The current study evaluated long-term survival and age-related
disparities in predictors of all-cause mortality following AMI in
unselected ‘‘real life’’ patients. The main ﬁndings of the study
include: ﬁrst, signiﬁcantly higher long-term mortality in older
patients compared with younger; moreover, signiﬁcantly higher
long-term mortality of patients discharged alive following AMI
compared with age-, gender-, and ethnicity-matched general
population (SMR = 2.2), and somewhat greater impact of AMI on
mortality in the young than in older patients compared to matched
general population; second, long-term all-cause mortality in the
older patients as well as in relatively young AMI patients can be
accurately predicted from simple, easily accessible clinical
information present at the time of initial hospital presentation
including a wide variety of noncardiovascular comorbidities; third,
differences in risk factors that are signiﬁcantly associated with
long-term mortality between older and younger populations were
found.
These differences include many risk factors that are predictive
only in the younger group and few that are predictive only in the
older group. Moreover, there were signiﬁcant disparities in the
prediction strength of numerous risk factors, most of whom have
stronger associations with long-term mortality in the younger
group. Although the age used for the deﬁnition of older or elderly
patients varies among trials from 55 to 80 years [8,20–22],
standard WHO deﬁnition of 65 years, reﬂecting also the most
common retirement age in Europe, was applied for this study.
Baseline characteristics of our entire cohort, the characteristics of
the older patients speciﬁcally, and the higher prevalence of
women, NSTEMI, comorbidities, and risk factors in the older
population are consistent with other similar cohorts of ‘‘real life’’
patients, applying similar age deﬁnitions [7,10]. Furthermore, the
lower rates of mechanical reperfusion and the signiﬁcantly
increased short- and long-term mortality rates after hospital
discharge in the elderly are in agreement with previous reports
[7,10].
Throughout the years various short- and long-term mortality
models have been reported [23–27]. Most of these models were
derived from clinical trial databases or speciﬁc subgroups of
patients with acute coronary syndromes. Patients with complica-
tions and comorbidity tend to be excluded from such trials, thus
limiting ‘‘real world’’ applicability. However, the database of the
current study, that served the development and validation of the
recently reported SAMI score [14], is based on an unselected
contemporary, ‘‘all comer’’ population.
The well-established GRACE score also has minimal exclusion
criteria and spans the whole spectrum of acute coronary syndrome
[27,28]. The GRACE score was found to accurately predict mortality
at 6 months and in a recent report the score performed well (c-
statistic 0.77) in predicting long-term mortality (5-year follow-up)
after AMI. However, the mean age of the population in the latter
study was between 65 and 67 years, whereas in the current and
similar reports it is a decade older; hence, the results of the GRACE
score is less applicable to older patients [29]. Roe et al. [7] recently
reported the CRUSADE long-term mortality model and risk score
that were retrospectively derived and validated on patients 65
years old with NSTEMI. The CRUSADE long-term mortality risk
score comprised 13 most clinically and statistically signiﬁcant
variables from the full model (based entirely on variables from
initial hospital presentation) and had comparable discrimination
in the derivation and validation samples (c-statistics 0.734 and
0.727, respectively) for up to 3-year mortality following AMI.
Furthermore, consistent with our ﬁndings, the authors found that
older patients with NSTEMI still face high mortality rates of
approximately 40% within 3 years of their events. However, our
Table 2
Cumulative mortality (percent of categories) according to the investigated variables by the age groups (univariate analysis); p values of the interaction models.
Variable Value(s) Age 65 years Age >65 years Interaction
Cumulative
mortality
HR 95% CI Cumulative
mortality
HR 95% CI p
Demographics
Age, years 1-Year increase 1.06*** (1.04; 1.08) 1.07*** (1.06; 1.08) 0.435
Gender Female/male 24.8/17.3 1.49* (1.1; 2.02) 72.9/67.2 1.16 (1.03; 1.3) 0.133
Ethnicity Arabs/Jews 26.3/17.9 1.52* (1.10; 2.1) 63.8/70.4 0.86 (0.68; 1.09) 0.006
Cardiovascular risk factors
Hypertension Yes/no 22.9/15.6 1.5** (1.15; 1.94) 68.7/71.2 0.91 (0.8; 1.02) 0.001
Dyslipidemia Yes/no 16.2/21.2 0.72* (0.52; 0.99) 63.3/70.8 0.78** (0.68; 0.91) 0.61
DM – all forms Yes/no 33.5/12.2 3.15*** (2.43; 4.09) 77.6/64.8 1.45*** (1.28; 1.63) <0.001
DM without recorded renal
or peripheral circulation
manifestations
Yes/no 28.8/14.9 2.09*** (1.6; 2.72) 74.2/67.8 1.2** (1.05; 1.36) <0.001
PVD Yes/no 45.3/15.8 3.63*** (2.67; 4.94) 83.5/66.2 1.57*** (1.36; 1.8) <0.001
Smoking Yes/no 15.8/23.1 0.65*** (0.5; 0.84) 65.3/71.0 0.84* (0.73; 0.98) 0.089
Renal diseases Yes/no 47.9/13.7 4.51*** (3.43; 5.93) 81.2/63 1.7*** (1.5; 1.92) <0.001
Obesity Yes/no 18.1/20.2 1.1 (0.82; 1.48) 61.5/71.2 0.72*** (0.61; 0.86) 0.018
Cardiac history
History of PCI Yes/no 23.8/17.8 1.37 (0.98; 1.92) 68.7/69.9 0.92 (0.76; 1.11) 0.045
History of CABG Yes/no 43.7/17.2 3.12*** (2.09; 4.62) 76.8/68.9 1.13 (0.93; 1.36) <0.001
Previous MI Yes/no 32.7/15.8 2.36*** (1.77; 3.13) 76.4/67.8 1.34*** (1.17; 1.54) <0.001
Mitral and aortic valves
disorders
Yes/no 31.7/17.1 2.05*** (1.46; 2.88) 76.0/67.9 1.21** (1.05; 1.39) 0.005
Cardiomegaly Yes/no 37.7/17.5 2.42*** (1.61; 3.64) 70.9/69.6 1.03 (0.84; 1.26) <0.001
CHF Yes/no 53.7/17.0 4.25*** (2.88; 6.28) 87.3/66.6 1.89*** (1.62; 2.2) <0.001
Atrial ﬁbrillation and ﬂutter Yes/no 41.5/17.3 2.81*** (1.88; 4.2) 82.4/66.4 1.5*** (1.3; 1.72) 0.004
Characteristics of AMI event,
type of AMI
STEMI/NSTEMI 17.6/21.1 0.813 (0.62; 1.07) 68.9/71.0 0.92 (0.81; 1.04) 0.44
Coronary angiography ﬁndings,
coronary artery disease
No or nonsigniﬁcant 18.9 1 36 1
Signiﬁcant one vessel 9.2 0.46* (0.22; 0.96) 42.2 1.18 (0.58; 2.42) 0.073
Signiﬁcant two vessels 15.5 0.8 (0.4; 1.59) 51.2 1.61 (0.81; 3.17) 0.156
Signiﬁcant three vessels
or signiﬁcant LMCA
16.7 0.88 (0.5; 1.71) 63.4 2.28* (1.17; 4.43) 0.047
Intervention for AMI Conservative 31.1 1 80 1
CABG 6.5 0.17*** (0.08; 0.37) 52.6 0.41*** (0.32; 0.54) 0.033
Thrombolytic therapy
or/and PCI
12.9 0.36*** (0.28; 0.47) 54.4 0.47*** (0.41; 0.54) 0.087
Echocardiography ﬁndings
Severe LV dysfunction Yes/no 46.7/14.3 4.16*** (2.87; 6.03) 84.4/61.8 2.12*** (1.75; 2.57) 0.002
Concentric or signiﬁcant LV
hypertrophy
Yes/no 32.4/16.0 2.14* (1.19; 3.85) 85.1/63.8 1.96*** (1.49; 2.57) 0.788
LV dilatation Yes/no 53.6/15.6 4.64*** (2.73; 7.89) 83.3/64.3 1.79*** (1.3; 2.47) 0.003
Elevated LV ﬁlling pressure Yes/no 42.3/14.5 1.52*** (1.34; 1.72) 79.8/62.3 1.17*** (1.09; 1.24) 0.152
Moderate or severe MR Yes/no 56.0/15.6 5.54*** (3.2; 9.57) 74.4/64.3 1.47** (1.14; 1.9) <0.001
Moderate or severe pulmonary
hypertension
Yes/no 50.0/16.2 3.83** (1.7; 8.65) 82.4/63.5 1.88*** (1.48; 2.39) 0.001
Left atrial dilatation Yes/no 23.5/16.0 1.25 (0.99; 1.58) 77.8/61.6 1.24*** (1.14; 1.35) 0.929
Signiﬁcant right ventricular
dysfunction
Yes/no 28.0/15.1 1.43*** (1.18; 1.73) 76.9/63.4 1.22*** (1.1; 1.36) 0.159
Moderate or severe tricuspid
regurgitation
Yes/no 70.0/15.6 7.29*** (4.21; 12.62) 78.9/63.9 1.65*** (1.29; 2.1) <0.001
Results of laboratory tests
Plasma sodium, meq./L <135/135 28.6/15.9 1.98*** (1.5; 2.63) 77.5/66.8 1.36*** (1.2; 1.55) 0.017
Plasma potassium, meq./L >5.1/5.1 29.9/16.2 2.02*** (1.51; 2.72) 77.3/67 1.35*** (1.18; 1.53) 0.013
Other disorders
Anemia Yes/no 28.6/14.1 2.28*** (1.76; 2.96) 77.1/61.3 1.59*** (1.4; 1.8) 0.013
Gastro-intestinal hemorrhage Yes/no 29.4/18.5 1.84 (0.76; 4.46) 88.2/69.1 1.68*** (1.25; 2.27) 0.484
COPD Yes/no 52.6/17.0 3.97*** (2.7; 5.83) 85.0/67.8 1.86*** (1.56; 2.21) <0.001
Malignant neoplasm Yes/no 61.1/18.0 4.81*** (2.62; 8.82) 85.9/68.8 1.94*** (1.53; 2.46) 0.006
Alcohol or drug addiction Yes/no 51.3/17.5 4*** (2.55; 6.38) 82.4/69.6 1.39 (0.82; 2.36) 0.003
Schizophrenia or psychosis Yes/no 52.9/18.1 4.08*** (2.09; 7.94) 52.9/69.4 1.62* (1.07; 2.45) 0.021
Neurological disorders Yes/no 20.0/18.6 1.07 (0.34; 3.35) 68.8/96.2 2.53*** (1.09; 3.37) 0.152
HR, hazard ratio; CI, conﬁdence interval; DM, diabetes mellitus; PVD, peripheral vascular disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass
graft; AMI, acute myocardial infarction; MR, mitral regurgitation; CHF, congestive heart failure; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation
myocardial infarction; LMCA, left main coronary artery; LV, left ventricular; COPD, chronic obstructive pulmonary disease.
* p < 0.05.
** p < 0.01.
*** p < 0.001.
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Table 3
Mortality risk according to the investigated variables by age groups (multivariate analysis); p values of the interaction model.
Variable Value(s) Age 65 years Age >65 years Interaction
AdjHR 95% CI AdjHR 95% CI p
Demographics
Age, years 1-Year increase 1.02 (1; 1.04) 1.06*** (1.05; 1.07) 0.001
Cardiovascular risk factors
DM without recorded renal or
peripheral circulation manifestations
Yes/no 1.59*** (1.19; 2.12) 1.37*** (1.2; 1.57) 0.348
PVD Yes/no 2.15*** (1.51; 3.06) 1.37*** (1.19; 1.57) 0.065
Renal diseases Yes/no 2.52*** (1.86; 3.41) 1.51*** (1.31; 1.75) <0.001
Previous MI Yes/no 1.88*** (1.38; 2.57) 1.18* (1.02; 1.36) 0.006
Coronary angiography ﬁndings,
coronary artery disease
(compared to no or nonsigniﬁcant)
Signiﬁcant one vessel 0.83 (0.37; 1.89) 1.56 (0.75; 3.28) 0.258
Signiﬁcant two vessels 0.95 (0.44; 2.04) 2 (0.99; 4.05) 0.155
Signiﬁcant three vessels
or signiﬁcant LMCA
0.83 (0.4; 1.71) 2.24* (1.13; 4.45) 0.048
Intervention for AMI
(compared to conservative)
CABG 0.1*** (0.04; 0.22) 0.46*** (0.34; 0.63) 0.001
Thrombolytic therapy
or/and PCI
0.48*** (0.33; 0.71) 0.75* (0.6; 0.93) 0.053
Echocardiography ﬁndings
Severe LV dysfunction Yes/no 1.57* (1.02; 2.39) 1.49*** (1.22; 1.82) 0.814
Moderate or severe MR Yes/no 2.14** (1.21; 3.81) 1.16 (0.89; 1.51) 0.06
Left atrial dilatation Yes/no 0.97 (0.76; 1.25) 1.24*** (1.13; 1.35) 0.075
Results of laboratory tests
Plasma sodium, meq./L <135/135 1.74*** (1.29; 2.35) 1.2** (1.05; 1.37) 0.027
Other disorders
Anemia Yes/no 1.89*** (1.42; 2.51) 1.38*** (1.21; 1.57) 0.045
COPD Yes/no 2.64*** (1.76; 3.97) 2.01*** (1.68; 2.4) 0.211
Malignant neoplasm Yes/no 3.35*** (1.74; 6.47) 1.57*** (1.23; 2) 0.036
Alcohol or drug addiction Yes/no 3.7*** (2.27; 6.02) 1.48 (0.87; 2.53) 0.013
Schizophrenia or psychosis Yes/no 3.01** (1.44; 6.29) 1.47 (0.96; 2.25) 0.096
Neurological disorders Yes/no 0.44 (0.11; 1.81) 2.31*** (1.75; 3.1) 0.023
AdjHR, adjusted hazard ratio; CI, conﬁdence interval; DM, diabetes mellitus; PVD, peripheral vascular disease; PCI, percutaneous coronary intervention; CABG, coronary
artery bypass graft; AMI, acute myocardial infarction; MR, mitral regurgitation; CHF, congestive heart failure; LMCA, left main coronary artery; LV, left ventricular; COPD,
chronic obstructive pulmonary disease.
* p < 0.05.
** p < 0.01.
*** p < 0.001.
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longer follow-up period, inclusion of noncardiovascular risk
factors and comorbidity, the applicability to all types of AMI
and the comparison of the discriminating factors and strength of
prediction between the older and the younger population, thus
pointing out speciﬁc targets of potential intervention for the older
group. Kala et al. [10] evaluated age-related differences in
treatment strategies, results of PCI procedures and long-term
mortality (5 years) of patients with all types of AMI. Although, for
the most part not statistically signiﬁcant, the authors report that
initial signs of heart failure (Killip II–IV), the presence of DM and
previous MI, ﬁnal thrombolysis in myocardial infarction ﬂow, and
the infarct-related artery are signiﬁcant long-term negative
predictors but do not play an important role in the older group
(>65 years) as they do in the younger. In addition, age was found to
be a stronger predictor in the older age group. These ﬁndings of
tendency toward stronger long-term prediction of risk factors and
other comorbidities, in the younger population are consistent with
our ﬁndings. However, more parameters were found to be
signiﬁcantly associated with the outcome in our study, possibly
due to the longer follow-up period. Although we have not
elaborately evaluated results of the coronary angiography or the
PCI procedures (except the number of arteries signiﬁcantly
involved), that are not usually easily accessible after discharge,
PCI was found to be signiﬁcantly associated with reduced mortality
in our study, consistently with the ﬁndings of Kala et al. [10].
However, contrary to our ﬁndings of borderline increasedprotective effect in the younger versus the older age group, Kala
et al. reported that PCI in the older patients seems to be even more
important (had a stronger protective effect) than in younger
patients. This inconsistency could stem from the much higher rate
of PCI in both age groups in their study compared to ours and
possibly from advances in the instruments, the technique, and
periprocedural and secondary prevention treatments over the
years (our patients were treated approximately 5 years earlier).
Alternatively, it is possible, but less likely, that the additive
protective effect of PCI in the older group diminishes over time
(between 5 and 10 years).
The age-related disparities in the prognostic factors found in
the current study could be attributed to the following reasons. Age-
related fundamental changes in the anatomy and physiology of the
aging heart and cardiovascular system included among others:
decreased vascular compliance, endothelial dysfunction, ventricu-
lar hypertrophy and remodeling, ﬁbrosis leading to diastolic
dysfunction, and diminished response to adrenergic stimulation
[2,30–32]. Moreover, physiological aging of other systems included
alterations in renal, pulmonary, and hepatic function, altered
coagulation, and ﬁbrinolytic activity (increased factor VIII,
ﬁbrinogen, and plasmin/antiplasmin complex) [2]. These age-
related changes could inﬂuence the natural history and the
distribution of the mortality causes and hence contribute to the
age-related differences in the discriminating ability of various risk
factors (e.g., left atrial dilatation, a known contributor to atrial
ﬁbrillation, was independently associated with long-term
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association is mediated through cerebrovascular events, which are
known to be more common among older patients with atrial
ﬁbrillation as evident in the CHADS score) [33].
In our study the older group differs demographically from the
younger group; a lower rate of male gender and minorities were
found, which are known to have a different long-term risk proﬁle
[34,35].
Although we did measure comorbidities that are not typically
collected in large cardiovascular studies (e.g., malignancies,
psychiatric, and neurological disorders), it is highly possible that
other nonmeasured parameters such as frailty status, post-
discharge management, and lifestyle issues have much stronger
inﬂuence on long-term mortality in older compared to younger
patients with AMI [7,36].
There are acute and long-term differences in treatment, and
success rates of treatments in the older versus younger patients
[37]. Elderly patients are often subjected to more conservative
treatment strategies, which at times diverge signiﬁcantly from
recommendations in accepted guidelines [2]; thus, various
insufﬁciently managed risk factors (e.g., hypertension, renal
diseases, and dyslipidemia) could alter mortality rates and causes
in the elderly.
Limitations
The data collection of baseline characteristics was retrospec-
tive. The endpoint was all-cause mortality, which limited the
possibility of evaluating disparities in cause-speciﬁc mortality
between the elderly and the young, as an explanation for
disparities in predictors. The current study evaluated variables
from initial hospital presentation and did not assess disparities in
subsequent management, procedures, events, and compliance.
Conclusions
Differences in risk factors signiﬁcantly associated with long-
term (10-year) all-cause mortality following AMI between older
and younger populations were found. These ﬁndings can be used
for more accurate risk stratiﬁcation of elderly patients, for
prioritizing targets of potential postdischarge interventions and
mortality reduction in these high-risk patients, and for measure-
ments and comparisons of providers’ outcomes.
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